Investor Presentaiton

SELECT TRIALS - MIRIKIZUMAB Lilly Completion Study Indication* Title Phase Patients Primary Outcome* ** Primary Completion NCT03926130 Crohn's A Study of Mirikizumab (LY3074828) in Participants With Disease Crohn's Disease (VIVID-1) 3 1100 Percentage of Participants Achieving Clinical Response at Week 12 and Endoscopic Response at Week 52 Aug 2023 Dec 2023 NCT04232553 Crohn's A Long-term Extension Study of Mirikizumab (LY3074828) Disease in Participants With Crohn's Disease (VIVID-2) 3 778 Percentage of Participants Achieving Endoscopic Response Jan 2025 Apr 2027 NCT03518086 Ulcerative Colitis An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT- 1) 3 1281 Percentage of Participants With Clinical Remission at Week 12 Jan 2021 Mar 2024 NCT03524092 Ulcerative Colitis A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT- 2) 3 1177 Percentage of Participants in Clinical Remission at Week 40 Nov 2021 Apr 2026 NCT03519945 Ulcerative Colitis A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3) 3 960 Percentage of Participants in Clinical Remission Jun 2025 Apr 2029 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Source: clinicaltrials.gov, July 13, 2023 2023 Q2 EARNINGS 222 42

View entire presentation